

# ASX Notification

Medibio Limited – 24 NOV 2016



To: Australian Stock Exchange  
From: Medibio Limited (ASX: MEB)  
Subject: Medibio enters into binding reseller agreement with Medtronic

## Medibio enters into binding integration and value-added reseller agreement with Medtronic

**Medibio Limited (Medibio)** has entered into a binding Integration and Value-Added Reseller Agreement (the "Agreement") with the Health Informatics & Monitoring division of Medtronic. Under the Agreement, Medibio has integrated Medtronic's Zephyr BioPatch™ medical products into Medibio's Digital Mental Health Platform as part of its mental health solution. The Agreement provides Medibio non-exclusive rights to purchase and re-sell Medtronic's Zephyr BioPatch™ medical products and accessories as part of its solution. The initial term of the Agreement is fifteen (15) months and allows Medibio to resell the Zephyr™ products in the United States of America and in any other countries mutually agreed between the parties in future.

Medtronic and Medibio also intend to explore joint opportunities around Medibio's mental health solution with key clients.

### About Medibio Limited

Medibio (ASX: MEB), is a medical technology company that has developed an objective test to assist in the diagnosis of depression, chronic stress and other mental health disorders. Based on research conducted over 15 years at the University of Western Australia, this test utilizes patented (and patent pending) circadian heart rate variability and cloud based proprietary algorithms delivering a quantifiable measure to assist in clinical diagnosis. Medibio's depression diagnostic is being validated in clinical studies undertaken by Johns Hopkins University School of Medicine and The University of Ottawa, among others. The clinical trials will support Medibio's application to become the first FDA approved, objective, and evidence based approach to the diagnosis of mental health disorders. Medibio's technology also provides an objective method for the assessment of stress and mental wellbeing that can be translated to the workplace stress/wellbeing market, wearable technology, and App market. Located in Melbourne, VIC, Medibio is listed on the Australian Securities Exchange.

|  |   |   |
|--|---|---|
| <b>Further Information:</b>  |   | Website: <a href="http://www.medibio.com.au">www.medibio.com.au</a> |
| <b>Medibio Shareholder Enquiries to:</b><br>Kris Knauer<br>CEO and Director Medibio Limited<br><a href="mailto:kris.knauer@medibio.com.au">kris.knauer@medibio.com.au</a><br>T: +61 (0)411 885 979 | <b>Medibio Media Enquiries to:</b><br>Peter Taylor<br>NWR Communications<br><a href="mailto:peter@nwrcommunications.com.au">peter@nwrcommunications.com.au</a><br>T: +61 (0)412 036 231 |   |